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Abstract
Nicotinic acid is a unique cholesterol modifying agent that exerts favorable effects on all cholesterol
parameters. It holds promise as one of the main pharmacological agents to treat mixed dyslipidemia
in metabolic syndrome and diabetic patients. The use of nicotinic acid has always been haunted with
concerns that it might worsen insulin resistance and complicate diabetes management.
We will discuss the interaction between phosphorous metabolism and carbohydrate metabolism
and the possibility that worsening of insulin resistance could be related to adrug induced alteration
in phosphorous metabolism, and the implications of that in medical management of diabetes and
metabolic syndrome patients with mixed dyslipidemia.
Background
Nicotinic acid functions in the body after conversion to
nicotinamide adenine dinucleotide (NAD) in the NAD
coenzyme system. Niacin reduces total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C), triglycerides
(TG), apolipoprotein B-100 (Apo B) and Lipoprotein (a)
(Lp (a)). Niacin increases high-density lipoprotein choles-
terol (HDL-C), apolipoprotein A-I (Apo A-I), lipoprotein
A-I, and HDL2: HDL3 ratio. The severity and type of
underlying lipid abnormality determines the extent of
response to niacin treatment [1].
There is evidence suggesting that niacin reduces the risk of
a coronary artery or cerebrovascular disease in the setting
of secondary prevention, and when combined with a bile
acid-sequestrant, promotes regression and decreases pro-
gression of atherosclerotic cardiovascular disease [2,3].
Niacin is known to cause transient, small but statistically
significant dose-related reductions in phosphorous levels.
These effects were studied for extended release niacin in
placebo-controlled trials, mean percentage changes from
baseline (± standard error) in phosphorous were (-4.0 ±
1.3) for the 500 mg once daily dose, (-7.2 ± 1.1) for the
1000 mg once daily dose, (-9.1 ± 1.1) for the 1500 mg
once daily dose, and (-12.6 ± 1.6) for the 2000 mg once
daily dose [4].
Presentation of the hypothesis
It has been long known that niacin induces impaired fast-
ing glucose. I was also suggested that this effect is most
likely transient. The mechanism behind this phenome-
non has not been fully elucidated [5].
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Multiple studies were conducted to study effects of nico-
tinic acid on exacerbating insulin resistance. One retro-
spective study suggested that the use of moderate doses of
extended release nicotinic acid (average, 1000 mg/d) in
reasonably controlled diabetics was associated with
improved glycemic control with HbA1c levels decreased
by 0.5% ± 0.3% due to aggressive hypoglycemic therapy;
as most of these patients had their insulin or oral diabetes
regimen intensified [6]. Another retrospective study using
unmodified niacin concluded similar results [7].
The (ADMIT) trial, was one of the first studies to demon-
strate the safety of nicotinic acid in patients with diabetes.
Diabetic patients (468 participants, 125 with diabetes and
peripheral arterial disease) were randomized to treatment
with either placebo or niacin (2500 mg/d) for 18 weeks.
Patients randomized to niacin therapy had modest
increases in fasting glucose (+8 mg/dL). There was no sig-
nificant change in HbA1c levels or in diabetes treatment
regimen in the niacin-treated diabetic patients group [8].
Another prospective Trial (ADVENT), was a 16-week, dou-
ble-blind, placebo-controlled trial, 148 patients were ran-
domized to placebo (n = 49) or 1000 (n = 45) or 1500
mg/d (n = 52) of extended release niacin. Fasting plasma
glucose levels in both treatment groups were unchanged
from placebo at the study's end. Meanwhile, the mean
HbA1c levels were only slightly elevated in the 1500 mg
arm, compared with placebo. The 1500 mg nicotinic acid
arm required a small increase in anti-diabetic treatment
regimen [9].
It appears from the clinical data presented above, that nic-
otinic acid at higher doses could results in alterations in
glycemic control of patients with an already abnormal
glucose metabolism.
Phosphate is primarily an intracellular anion. Insulin is
implicated in the transport of glucose and phosphate
from the intra-cellular to the extra-cellular space. Studies
have suggested a link between decreased serum phospho-
rous and disturbed carbohydrate metabolism, eventually
leading to hyperglycemia [10,11]. Chronic hypophos-
phatemia inhibits glucose transport. Further more,
reduced serum phosphorous levels significantly decrease
the phosphorylation of carbohydrate intermediates in gly-
colysis and glycogenesis.
It seems intuitive to suspect that the transient decrease in
plasma phosphorous level might explain the transient dis-
turbance in carbohydrate metabolism and hyperglycemia
induced by nicotinic acid. Also, studies suggest the exist-
ence of a dose response relationship in both instances.
One way to test this hypothesis will be to administer nic-
otinic acid to both healthy subjects, and to those with
impaired fasting glucose or subjects with diabetes, then
measure simultaneously at different doses serum phos-
phorous, and correlate the changes to changes in serum
glucose and serum insulin either individually or com-
bined as a measure of insulin resistance.
It will be of interest to study if such a relationship exists in
patients with the metabolic syndrome diagnosis, since lit-
erature suggests the existence of an abnormal phospho-
rous metabolism in these patients [10,12].
Implications of the hypothesis
This hypothesis has several important insights and impli-
cations:
1. If valid, it suggests the possibility of a simple clinical
way to prevent nicotinic acid induced worsening of glyc-
emic control by dietary phosphorous supplementation,
eliminating the need to intensify expensive diabetic regi-
mens in diabetic patients that need nicotinic acid treat-
ment.
2. If valid, it will aid in lessening the theoretical anxiety of
the possibility of precipitating diabetes in glucose intoler-
ant or metabolic syndrome patients in need of nicotinic
acid treatment for the management of dyslipidemia.
3. Metabolic syndrome and diabetics stand to benefit
greatly from the new evidence implicating the importance
of increasing HDL-cholesterol in cardiovascular event
reduction.
4. This hypothesis offers new insights into the mechanism
of development of glucose intolerance.
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